Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501267 · ClinicalTrials.gov registry record · Phase 1
A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
A Phase 1 study of Overactive Bladder, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00501267: Completed Phase 1 study of Overactive Bladder, sponsored by GlaxoSmithKline.
NCT00501267 is a Phase 1 study of Overactive Bladder that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants, below the 207-participant average among 46 other Overactive Bladder trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00501267, a Phase 1 study of Overactive Bladder, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together
Conditions Studied
Interventions
- DRUG solabegron and oxybutynin
Study Locations (1)
Washington
- GSK Investigational Site - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-06 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
What the finished NCT00501267 record still lists
NCT00501267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 207-participant average among 46 other Overactive Bladder trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Overactive Bladder appearing as the primary indexed condition, and to 1 intervention - of which solabegron and oxybutynin is the first listed.
NCT00501267 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00501267 about?
NCT00501267 is a clinical study titled "A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder". The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together
What is the current status of trial NCT00501267?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-06. Estimated completion is 2007-08.
What conditions does trial NCT00501267 study?
This clinical trial studies the following conditions: Overactive Bladder.
What interventions are being tested in trial NCT00501267?
The interventions under investigation include: solabegron and oxybutynin (DRUG).
Who is sponsoring clinical trial NCT00501267?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00501267 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00501267's enrollment target sits among peer trials
24 39th of 46 higher than 8 of 46 other Overactive Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overactive Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced-dose Botox for Urgency Incontinence Among Elder Females
ACTIVE NOT RECRUITING · Phase 1
-
Botulin-A Toxin Instillations and Overactive Bladder
COMPLETED · Phase 1
-
A Two-Part Study to Determine: Best Medication Formulation and Food Effect
COMPLETED · Phase 1
-
Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB
COMPLETED · Phase 1
-
Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead
RECRUITING · NA
-
Bladder Botox UTI Antibiotic Prophylaxis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia